Sarah Kathryn Rouan serves as Executive at NAVIDEA BIOPHARMACEUTICALS, INC., where they oversee executive responsibilities. Since joining the company, Sarah Kathryn Rouan has executed 12 insider transactions totaling $1.4M, demonstrating a bearish approach to their equity position. Their most recent transaction on Jan 2, 2026 involved receiving (via award) 20,400 shares valued at $0.
Sarah Kathryn Rouan currently holds 20,400 shares of NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Sarah Kathryn Rouan has been a net seller of NAVB stock. They have purchased $4.9K and sold $1.4M worth of shares.
Sarah Kathryn Rouan's most recent insider trade was on Jan 2, 2026, when they sold 20,400 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Feb 8, 2024 | VKTX | $701.3K | Sale | 25,000 | $28.05 | Planned |
| Feb 8, 2024 | VKTX | $208.0K | Option Exercise | 25,000 | $8.32 | Planned |
| Jan 19, 2024 | VKTX | $249.6K | Option Exercise | 30,000 | $8.32 | Planned |
| Jan 19, 2024 | VKTX | $691.5K | Sale | 30,000 | $23.05 | Planned |
| Jun 30, 2021 | NAVB | $0 | Award | 4,892 | $N/A | Discretionary |
| Jan 13, 2021 | NAVB | $0 | Award | 2,500 | $N/A | Discretionary |
| Feb 6, 2020 | NAVB | $0 | Award | 2,500 | $N/A | Discretionary |
| May 17, 2019 | NAVB | $4.9K | Purchase | 3,350 | $1.46 | Discretionary |
| Feb 7, 2019 | NAVB | $0 | Award | 50,000 | $N/A | Discretionary |
| Jan 2, 2019 | NAVB | $0 | Award | 50,000 | $N/A | Discretionary |